Convergent Therapeutics, Inc.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Convergent Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2024).
SEC Form D · Aug 2024
The industry group it chose in its notices: Biotechnology.
SEC Form D · Aug 2024
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of Convergent Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Alexander Brown | Executive officer | Aug 2024 |
| Eric Sullivan | Executive officer | Aug 2024 |
| Neil Bander | Executive officer | Aug 2024 |
| Philip Kantoff | Executive officer | Aug 2024 |
| Jake Simson | Director | Aug 2024 |
| Jim Trenkle | Director | Aug 2024 |
| Neil Bander | Director | Aug 2024 |
| Philip Kantoff | Director | Aug 2024 |
| Tal Zaks | Director | Aug 2024 |